2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - La Nouvelle C
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Palliative Care, Clinical Practice (Health Services and Quality), Quality of Care, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

155 Associations between baseline psychosocial factors and early CAR-T clinical and patient-reported survivorship outcomes in real-world patients with multiple myeloma: Preliminary analyses from an ongoing prospective study

Laura B. Oswald, PhD, Xiaoyin Li2, Alicia Richards, PHD, MS3, Gabriel De Avila4, David Scheiber-Camoretti5, Tiara Boykins6, Oanh Nguyen7, Yvelise Rodriguez8, Crystal Bryant9, Paige Lake10, Rachid Baz, MD11, Kenneth H. Shain, MD, PhD12, Brandon Blue, MD13, Ariel Grajales-Cruz, MD14, Fabiana Perna, MD, PhD15, Melissa Alsina, MD16, Ciara Louise L Freeman, MD, PhD17, Omar Alexis Castaneda Puglianini, MD18, Taiga Nishihori, MD19, Hien Liu, MD20, Frederick L. Locke, MD21, Heather Jim, PhD22, Alex Soupir23, Brent Small24, Doris K. Hansen, MD25, Lauren C Peres, PhD, MPH26
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Moffitt Cancer Center, Tampa, Florida, United States
14 Moffitt Cancer Center, Tampa, Florida, United States
15 Moffitt Cancer Center, Tampa, Florida, United States
16 Moffitt Cancer Center, Tampa, Florida, United States
17 Moffitt Cancer Center, Tampa, Florida, United States
18 Moffitt Cancer Center, Tampa, Florida, United States
19 Moffitt Cancer Center, Tampa, Florida, United States
20 Moffitt Cancer Center, Tampa, Florida, United States
21 Moffitt Cancer Center, Tampa, Florida, United States
22 Moffitt Cancer Center, Tampa, Florida, United States
23 Moffitt Cancer Center, Tampa, Florida, United States
24 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
25 Moffitt Cancer Center, Tampa, Florida, United States
26 Moffitt Cancer Center, Tampa, Florida, United States

Background: Chimeric antigen receptor T-cell therapy (CAR-T) is revolutionizing care for patients with relapsed/refractory multiple myeloma (RRMM), but real-world survivorship data are limited. Our team is investigating CAR-T clinical and patient-reported survivorship outcomes in an ongoing prospective study of RRMM patients treated with CAR-T in standard of care. This study is guided by a psychoneuroimmunology framework, which posits that psychosocial factors (e.g., chronic stress, social support) can alter immune regulation and inflammatory signaling, thereby influencing clinical and patient-reported outcomes. We performed preliminary analyses among a subset of participants to explore hypothesized associations between pre-CAR-T psychosocial factors (i.e., depression, anxiety, social support) and early clinical outcomes (i.e., clinician-graded toxicities, treatment response) and patient-reported survivorship outcomes (i.e., health-related quality of life [HRQOL], symptom burden).

Methods: Patients with RRMM treated with standard of care CAR-T at Moffitt Cancer Center completed surveys pre-lymphodepleting chemotherapy (baseline, BL) and approximately 90 days post-CAR-T (D90). BL psychosocial factors were assessed with Patient-Reported Outcomes Measurement Information System (PROMIS) short forms. D90 HRQOL was assessed with the Functional Assessment of Cancer Therapy-General (FACT-G). D90 symptom burden was assessed with a toxicity index calculated using items from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clinical data were abstracted from electronic medical records. Multivariable logistic and linear regression models were used to evaluate the associations of each BL psychosocial factor with D90 clinical and patient-reported survivorship outcomes, respectively, adjusting for age, gender, race and ethnicity, marital status, ECOG performance status, extramedullary disease, high-risk cytogenetics, and high bone marrow burden. Results are reported as odds ratios (OR) or regression coefficients (B) with 95% confidence intervals (CIs).

Results: Participants (N=72) were an average of 66.7 years old (SD=9.2, range 45-83), mostly male (65%) and non-Hispanic White (80%), with median 3 prior lines of therapy (range 1-6). Most were treated with ciltacabtagene autoleucel (97%). Adjusting for demographic and clinical characteristics, two BL psychosocial factors were associated with greater odds of non-immune effector cell-associated neurotoxicity syndrome (non-ICANS) neurotoxicity: more BL anxiety (OR=1.13, 95% CI [1.02, 1.27], p=0.030) and more BL social isolation (OR=1.16, 95% CI [1.04, 1.31], p=0.012). Several BL psychosocial factors were associated with better D90 HRQOL: less BL anxiety (B=-0.92, 95% CI [-1.56, -0.28], p=0.006) and social isolation (B=-1.39, 95% CI [-1.97, -0.81], p<0.001), as well as more BL companionship (B=1.16, 95% CI [0.49, 1.83], p=0.001), emotional support (B=1.06, 95% CI [0.25, 1.88], p=0.012), and information support (B=0.80, 95% CI [0.08, 1.53], p=0.031). No BL psychosocial factors were associated with cytokine release syndrome (CRS; any, grade ≥2), ICANS (any, grade ≥2), treatment response (best overall response, best complete response or better), or D90 symptom burden (p-values>0.05).

Conclusions: This ongoing prospective study is the first to investigate CAR-T clinical and patient-reported survivorship outcomes within an evidence-based psychoneuroimmunology framework among RRMM patients treated with CAR-T as standard of care. Controlling for key demographic and clinical factors, pre-CAR-T anxiety and social support were associated with risk of non-ICANS neurotoxicity and D90 HRQOL, with less BL anxiety and better BL social support indicators associated with better outcomes. These preliminary findings indicate that pre-treatment psychosocial factors may be important for both clinician- and patient-reported outcomes after CAR-T, and they identify anxiety and social support as potential pre-CAR-T intervention targets to improve outcomes. Additional analyses with the full study cohort are needed to confirm these preliminary findings and to investigate other hypothesized relationships between psychosocial and immune-related factors and clinician- and patient-reported survivorship outcomes within a psychoneuroimmunology framework.

Laura B. Oswald, PhD: No relevant conflicts of interest to declare.